Why the study?
Does paroxetine prevent depressive symptoms in hepatitis C virus-infected patients undergoing interferon-alpha/ribavirin treatment?
Population
61 hepatitis C virus-infected patients undergoing interferon-alpha/ribavirin treatment
Comparison
Paroxetine begun 2 weeks before and continued… vs Placebo
Design
RCT, randomly assigned, double-blind, placebo-controlled
Follow-up
24 weeks during treatment
Authors
Loading...
Supports paroxetine to lessen depressive symptoms in HCV patients with baseline MADRS >3 on interferon; extends prophylaxis evidence to this population.
Does paroxetine prevent depressive symptoms in hepatitis C virus-infected patients undergoing interferon-alpha/ribavirin treatment?
Paroxetine pre-treatment may reduce the severity of depressive symptoms in hepatitis C patients with elevated baseline depressive symptoms undergoing interferon-alpha/ribavirin therapy.
Raison et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: